Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell Carcinoma

Sponsor
The First Affiliated Hospital of Zhengzhou University
Study ID
NCT05189184
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a prospective, open-labelled study to evaluate the efficacy and safety of Camrelizumab in Combination With Apatinib mesylate Plus Albumin-bound paclitaxel and cisplatin as the First Line Treatment of Metastatic or Recurrent, UnresectableHead and Neck Squamous Cell Carcinoma. The objective response rate (ORR) will be evaluated as the primary endpoints.

Key Dates

Start date
Mar 30, 2022
Status verified
Dec 2021
Primary completion
Mar 30, 2025
Completion
Mar 30, 2025

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Study group
    Inductive therapy with Camrelizumab and Apatinib Plus Albumin-bound paclitaxel and cisplatin

Primary Outcome Measure

Objective Response Rate (CR+PR) [ Time Frame: Time Frame: Up to 24 months ]

Related Studies